ArriVent BioPharma Investor Relations Material

ArriVent BioPharma Inc. is a clinical-stage biopharmaceutical company focused on the identification, development, and commercialization of innovative medicines to meet the unmet medical needs of patients with cancers. The company specializes in developing targeted cancer therapies, including for non-small-cell lung cancer (NSCLC) and other solid tumors. A key product in its pipeline is Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor.